Receptor for advanced glycation end products (RAGE), a multi-ligand transmembrane receptor of the immunoglobulin superfamily, has been observed to bind LPA and modulate LPA-mediated EMT in lung and breast cancer [85]. Here, AGER is linked to breast cancer.